首页 > 最新文献

Journal of Cutaneous Medicine and Surgery最新文献

英文 中文
Response to Reader Comment on: Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective. 对读者评论的回应：导航大疱性类天疱疮：诊断和治疗的共识建议——加拿大的观点。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251387646
Fiona E Lovegrove, Maxwell B Sauder, Asfandyar Mufti, Jennifer Beecker, Jan P Dutz, Mark G Kirchhof, P Regine Mydlarski, Kerri S Purdy, Perla Lansang
{"title":"Response to Reader Comment on: Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective.","authors":"Fiona E Lovegrove, Maxwell B Sauder, Asfandyar Mufti, Jennifer Beecker, Jan P Dutz, Mark G Kirchhof, P Regine Mydlarski, Kerri S Purdy, Perla Lansang","doi":"10.1177/12034754251387646","DOIUrl":"https://doi.org/10.1177/12034754251387646","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251387646"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Treatments for Erythema Dyschromicum Perstans: A Systematic Review. 持久性红斑动力学治疗的有效性和安全性：一项系统综述。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251408362
Rachel Creighton, Jia Qi Adam Bai, Ilya Mukovozov
{"title":"Efficacy and Safety of Treatments for Erythema Dyschromicum Perstans: A Systematic Review.","authors":"Rachel Creighton, Jia Qi Adam Bai, Ilya Mukovozov","doi":"10.1177/12034754251408362","DOIUrl":"https://doi.org/10.1177/12034754251408362","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251408362"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral JAK and TYK2 Inhibitors in the Management of Nail Psoriasis: An Evidence-Based Review. 口服JAK和TYK2抑制剂治疗甲型银屑病：基于证据的综述
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251409046
Jihad Abou Ali Waked, Siddhartha Sood, Abdul Aziz Abdul Ghafoor, Mohamad Jama, Abrahim Abduelmula, Jensen Yeung, Asfandyar Mufti
{"title":"Oral JAK and TYK2 Inhibitors in the Management of Nail Psoriasis: An Evidence-Based Review.","authors":"Jihad Abou Ali Waked, Siddhartha Sood, Abdul Aziz Abdul Ghafoor, Mohamad Jama, Abrahim Abduelmula, Jensen Yeung, Asfandyar Mufti","doi":"10.1177/12034754251409046","DOIUrl":"https://doi.org/10.1177/12034754251409046","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251409046"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biologics and Small-Molecule Inhibitors in Nummular Dermatitis: A Systematic Review. 钱币状皮炎的生物制剂和小分子抑制剂：系统综述。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251403194
Jaehyun Hwang, Yu Xuan Jin, Qi Zuo, Ilya Mukovozov
{"title":"Biologics and Small-Molecule Inhibitors in Nummular Dermatitis: A Systematic Review.","authors":"Jaehyun Hwang, Yu Xuan Jin, Qi Zuo, Ilya Mukovozov","doi":"10.1177/12034754251403194","DOIUrl":"https://doi.org/10.1177/12034754251403194","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251403194"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis. 阿布替尼和杜匹单抗治疗中重度特应性皮炎的疗效和安全性。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251404468
Xinlin Huang, Mi Zhang, Sheng Wang, Xue Wang

Objective: To evaluate efficacy and safety of abrocitinib and dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD).

Methods: A retrospective analysis of 104 patients with moderate-to-severe AD (January-June 2023) was conducted. Patients received either oral abrocitinib 200 mg/day (n = 51) or subcutaneous dupilumab 300 mg every 2 weeks (n = 53, baseline load 600 mg) for 24 weeks.

Results: At 4, 8, and 12 weeks posttreatment, patients in the abrocitinib group exhibited significantly lower Eczema Area and Severity Index (EASI) scores compared to the dupilumab group (P < .05). Additionally, patients in the abrocitinib group demonstrated significantly lower Numeric Rating Scale for Pruritus (P-NRS) scores at 4, 8, 12, 16, and 24 weeks posttreatment compared to the dupilumab group (P < .05). Furthermore, patients in the abrocitinib group showed significantly lower Dermatology Life Quality Index (DLQI) scores at 4, 8, 12, and 16 weeks posttreatment compared to the dupilumab group (P < .05). Compared with dupilumab group, EASI, P-NRS and DLQI levels in abrocitinib group were more significantly decreased. The incidence of conjunctivitis in dupilumab group was significantly higher than that in abrocitinib group (P < .05). The incidence of nausea in abrocitinib group was significantly higher than that in dupilumab group (P < .05).

Conclusion: Both abrocitinib and dupilumab can significantly relieve pruritus and improve quality of life in patients with moderate-to-severe AD at 24 weeks after treatment, but abrocitinib is more effective in relieving pruritus. Both abrocitinib and dupilumab have high safety, but require attention for gastrointestinal symptoms and conjunctivitis, respectively.

目的：评价阿布替尼联合杜匹单抗治疗中重度特应性皮炎（AD）的疗效和安全性。方法：对2023年1 - 6月104例中重度AD患者进行回顾性分析。患者接受口服abrocitinib 200 mg/天（n = 51）或每2周皮下注射dupilumab 300 mg (n = 53，基线负荷600 mg)，持续24周。结果：治疗后4周、8周和12周，阿布替尼组患者湿疹面积和严重程度指数（EASI）评分明显低于杜匹单抗组（P P P P P P P）。结论：治疗后24周，阿布替尼和杜匹单抗均能显著缓解中重度AD患者的瘙痒，改善患者的生活质量，但阿布替尼缓解瘙痒的效果更明显。阿布替尼和杜匹单抗安全性高，但分别需要注意胃肠道症状和结膜炎。
{"title":"Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.","authors":"Xinlin Huang, Mi Zhang, Sheng Wang, Xue Wang","doi":"10.1177/12034754251404468","DOIUrl":"https://doi.org/10.1177/12034754251404468","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate efficacy and safety of abrocitinib and dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD).</p><p><strong>Methods: </strong>A retrospective analysis of 104 patients with moderate-to-severe AD (January-June 2023) was conducted. Patients received either oral abrocitinib 200 mg/day (n = 51) or subcutaneous dupilumab 300 mg every 2 weeks (n = 53, baseline load 600 mg) for 24 weeks.</p><p><strong>Results: </strong>At 4, 8, and 12 weeks posttreatment, patients in the abrocitinib group exhibited significantly lower Eczema Area and Severity Index (EASI) scores compared to the dupilumab group (<i>P</i> < .05). Additionally, patients in the abrocitinib group demonstrated significantly lower Numeric Rating Scale for Pruritus (P-NRS) scores at 4, 8, 12, 16, and 24 weeks posttreatment compared to the dupilumab group (<i>P</i> < .05). Furthermore, patients in the abrocitinib group showed significantly lower Dermatology Life Quality Index (DLQI) scores at 4, 8, 12, and 16 weeks posttreatment compared to the dupilumab group (<i>P</i> < .05). Compared with dupilumab group, EASI, P-NRS and DLQI levels in abrocitinib group were more significantly decreased. The incidence of conjunctivitis in dupilumab group was significantly higher than that in abrocitinib group (<i>P</i> < .05). The incidence of nausea in abrocitinib group was significantly higher than that in dupilumab group (<i>P</i> < .05).</p><p><strong>Conclusion: </strong>Both abrocitinib and dupilumab can significantly relieve pruritus and improve quality of life in patients with moderate-to-severe AD at 24 weeks after treatment, but abrocitinib is more effective in relieving pruritus. Both abrocitinib and dupilumab have high safety, but require attention for gastrointestinal symptoms and conjunctivitis, respectively.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251404468"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to Care in Atopic Dermatitis Patients With Skin of Colour: A Systematic Review. 有色皮肤特应性皮炎患者的护理障碍：系统综述。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251408409
Miranda K Branyiczky, Shahnawaz Towheed, Maryam Khan, Rachel Asiniwasis, Mohannad Abu-Hilal
{"title":"Barriers to Care in Atopic Dermatitis Patients With Skin of Colour: A Systematic Review.","authors":"Miranda K Branyiczky, Shahnawaz Towheed, Maryam Khan, Rachel Asiniwasis, Mohannad Abu-Hilal","doi":"10.1177/12034754251408409","DOIUrl":"https://doi.org/10.1177/12034754251408409","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251408409"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Generalized Eruptive Keratoacanthoma of Grzybowski: A Systematic Review of Clinical Presentation, Associated Conditions, and Therapeutic Outcomes. 全身性发疹性角棘瘤：临床表现、相关条件和治疗结果的系统回顾。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251403192
Rachel Creighton, Raquel Lazarowitz, Christopher Shenouda, Yan Yu, Jumana AlRujaib, Ghassan Barnawi, Ilya Mukovozov
{"title":"Generalized Eruptive Keratoacanthoma of Grzybowski: A Systematic Review of Clinical Presentation, Associated Conditions, and Therapeutic Outcomes.","authors":"Rachel Creighton, Raquel Lazarowitz, Christopher Shenouda, Yan Yu, Jumana AlRujaib, Ghassan Barnawi, Ilya Mukovozov","doi":"10.1177/12034754251403192","DOIUrl":"https://doi.org/10.1177/12034754251403192","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251403192"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Cumulative Life Course Impairment in Canadian Patients With Psoriasis. 了解加拿大银屑病患者的累积生命过程损害。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251403190
Jennifer Beecker, Chih-Ho Hong, Hélène Veillette, Ron Vender, Jensen Yeung, Vinod Chandran, Christine Palmay

Cumulative life course impairment (CLCI) is the irreversible harm resulting from the chronic burden of disease, such as psoriasis. This cumulative impact encompasses physical, psychological, social, and emotional challenges that can significantly alter the life trajectory of a patient with psoriasis. The risk of CLCI and the impact of living with psoriasis are exacerbated when the disease is inadequately managed. Even with improvements in skin symptoms, psychological factors, such as anxiety about relapse, can persist, adding to the long-term burden. The development and validation of screening tools to better identify and assess CLCI may provide a valuable framework for clinical practice, supporting holistic care and serving as an effective measure for evaluating the long-term impact of new therapies.

累积生命过程损害（CLCI）是由慢性疾病负担（如牛皮癣）引起的不可逆转的伤害。这种累积影响包括身体、心理、社会和情感方面的挑战，可以显著改变牛皮癣患者的生活轨迹。当银屑病管理不当时，CLCI的风险和银屑病患者的生活影响会加剧。即使皮肤症状有所改善，心理因素，如对复发的焦虑，也会持续存在，从而增加长期负担。开发和验证筛选工具以更好地识别和评估CLCI，可能为临床实践提供有价值的框架，支持整体护理，并作为评估新疗法长期影响的有效措施。
{"title":"Understanding Cumulative Life Course Impairment in Canadian Patients With Psoriasis.","authors":"Jennifer Beecker, Chih-Ho Hong, Hélène Veillette, Ron Vender, Jensen Yeung, Vinod Chandran, Christine Palmay","doi":"10.1177/12034754251403190","DOIUrl":"https://doi.org/10.1177/12034754251403190","url":null,"abstract":"<p><p>Cumulative life course impairment (CLCI) is the irreversible harm resulting from the chronic burden of disease, such as psoriasis. This cumulative impact encompasses physical, psychological, social, and emotional challenges that can significantly alter the life trajectory of a patient with psoriasis. The risk of CLCI and the impact of living with psoriasis are exacerbated when the disease is inadequately managed. Even with improvements in skin symptoms, psychological factors, such as anxiety about relapse, can persist, adding to the long-term burden. The development and validation of screening tools to better identify and assess CLCI may provide a valuable framework for clinical practice, supporting holistic care and serving as an effective measure for evaluating the long-term impact of new therapies.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251403190"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HPV Vaccination Coverage Among Inuit Youth in Ungava Bay, Nunavik. 努那维克Ungava湾因纽特青年的HPV疫苗接种覆盖率。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251408419
Arafat Atique, Meghan Kanou, Naomy Leclerc, Annie Kumarluk, Nathalie Boulanger, Elena Netchiporouk, Richard Chamberland, Justin Grenier, Ivan V Litvinov
{"title":"HPV Vaccination Coverage Among Inuit Youth in Ungava Bay, Nunavik.","authors":"Arafat Atique, Meghan Kanou, Naomy Leclerc, Annie Kumarluk, Nathalie Boulanger, Elena Netchiporouk, Richard Chamberland, Justin Grenier, Ivan V Litvinov","doi":"10.1177/12034754251408419","DOIUrl":"https://doi.org/10.1177/12034754251408419","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251408419"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ramsay Hunt Syndrome. 拉姆齐·亨特综合症。
IF 3.9 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery
Pub Date : 2025-12-26 DOI: 10.1177/12034754251396817
Arun Inamadar
{"title":"Ramsay Hunt Syndrome.","authors":"Arun Inamadar","doi":"10.1177/12034754251396817","DOIUrl":"https://doi.org/10.1177/12034754251396817","url":null,"abstract":"","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251396817"},"PeriodicalIF":3.9,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Journal of Cutaneous Medicine and Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1